• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Kalytera identifies sites for planned GvHD clinical trials

Kalytera identifies sites for planned GvHD clinical trials

April 26, 2017
CenterWatch Staff

Kalytera Therapeutics, a clinical-stage biopharmaceutical company developing next-generation cannabinoid- derived therapeutics, has developed the multicenter location component of the plan for the proposed clinical trials to evaluate cannabidiol (CBD) for the prevention and treatment of Graft versus Host Disease (GvHD). Kalytera is developing this clinical trial plan with the intent of obtaining FDA and EMEA approval for commercialization.

Kalytera expects to finalize and publish the details of its clinical trial plan during the current quarter ending June 30, 2017. The plan will include the clinical trial designs, the anticipated timeline for initiation and completion, as well as the principal endpoints. The trials are intended to build on the encouraging data seen in the recently completed phase IIa clinical trial.

The European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting brings together thought leaders from Europe and the world to explore the latest allogenic hematopoietic stem cell transplantation (HCT) and cellular therapy research. Having met and conferred with many of the leading authorities at EBMT, Dr. Andrew L. Salzman, Kalytera’s chief executive officer, and Dr. Sari Prutchi Sagiv, Kalytera’s vice president of Scientific Operations, have developed a multi-center site plan for Kalytera’s planned clinical trials.

“Kalytera’s recent groundbreaking clinical trial with CBD as a treatment for GvHD generated a great deal of excitement at EBMT,” said Salzman. “The EBMT annual meeting brings together the world’s leading authorities in HCT, a lifesaving procedure for a number of diseases. HCT patients will benefit tremendously if the risk of GvHD can be substantially reduced.

“Based on the encouraging results from our Phase 2a studies, we believe that CBD has the potential to help patients with GvHD who routinely fail first-line therapy with steroids. Kalytera intends to undertake additional clinical studies in an effort to obtain regulatory approval to use CBD for the treatment and prevention of GvHD. Under Dr. Sagiv’s direction, we are working to complete our next, major clinical trial plan. We look forward to publishing the details of that plan this quarter.”

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing